Screening Carotid Artery and Intracranial Arteries by Ultrasound in Chinese Population With Transient Ischemic Attack and Ischemic Stroke: a Multi-center Registry Study

The purpose of this multicenter study is to investigate the extra-/intra-cranial atherosclerosis distribution pattern in chinese populations with transient ischemic attack and ischemic stroke and analyze the influencing factors of atherosclerosis distribution pattern.

Start Date01 Jun 2015

Sponsor / Collaborator

Xuanwu Hospital Capital Medical University

[+15]

NCT00654576

/ CompletedPhase 4IIT

Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia:One-Year Follow up.

Antipsychotic alone is limit to improve the overall outcome of schizophrenia and has a high discontinue rate.To solve these problems, we provide practical and available psychosocial intervention. We hypothesize that there will be significant difference in the overall effectiveness between antipsychotic and antipsychotic combination with psychosocial intervention.

Start Date01 Feb 2005

Sponsor / Collaborator

Central South University

[+6]

100 Clinical Results associated with The Second People's Hospital of Hunan Province

0 Patents (Medical) associated with The Second People's Hospital of Hunan Province

Literatures (Medical) associated with The Second People's Hospital of Hunan Province

01 Dec 2025·Journal of Orthopaedics

Comparison of biomechanics between two different external fixation methods in the treatment of A1b tibial fractures based on finite element analysis

Article

Author: Fang, Shitao ; Mi, Lei ; Guo, Jinkun ; Wang, Yun ; Zhang, Ling ; Zhang, Ming

ObjectiveTo compare the biomechanical stability between two different external fixation methods (locked steel plates versus external fixation frame) for the treatment of A1b tibial fractures based on finite element analysis, and to provide theoretical reference for clinical application.MethodsBased on CT data of the left tibia from a healthy male volunteer, a normal three-dimensional (3D) tibial model was constructed using modeling software, which was further derived into a A1b tibial fracture model. Then, On the basis of the fracture model constructed above, the finite element models of locking compression plate and unilateral external fixator were fixed respectively. Further, 4 different test conditions (i.e., 4-point bending, axial compression, clockwise torsion, and counterclockwise torsion) were simulated under the same loading and constraint conditions for both models, in order to comparatively evaluate the equivalent peak stress and peak overall displacement of the fracture site between the two methods.ResultsFrom the experimental data corresponding to the maximum load under 4 different test conditions, it was found that the peak stress of tibia and the equivalent peak stress of fractured tibia with external fixation was roughly ranged 49.16-269.59 MPa and 34.99-559.58 MPa in the two fixation methods under various test conditions. Overall, external fracture fixation with locked steel plates showed a greater equivalent peak stress and a smaller peak overall tibial displacement than that with external fixation frame did.ConclusionsLocked steel plates may be superior external fixation frame in terms of biomechanical properties in the treatment of A1b tibial fractures, and can be used as an alternative option for patients who cannot tolerate external fixation frame.

21 Apr 2025·Cancer Research

Abstract 5357: Mutational landscape and tyrosine kinase inhibitor sensitivity in EGFR L833 and H835 mutated non-small cell lung cancer

Author: Ou, Qiuxiang ; Yin, Wei ; Chen, Hanlin ; Huang, Long ; Zeng, Fanxu ; Wu, Xue ; Ren, Dou ; Pang, Jiaohui ; Jiang, Chengchuan ; Yang, Nong ; Wu, Xiaoying ; Tang, Haimeng ; Zhang, Weiwei ; Huang, Peng ; He, Weifeng

AbstractBackground:EGFR L833 and H835 mutations account for 0.5% of EGFR-mutated non-small cell lung cancer (NSCLC) cases and are not classified as sensitive mutations to EGFR tyrosine kinase inhibitors (TKIs) according to NCCN guidelines, while chemotherapy remains the standard of care for patients with these mutations. Previous case reports have shown favorable EGFR-TKIs efficacy in patients with EGFR L833 and H835 mutations, this has yet to be validated in larger cohorts.Methods:DNA sequencing data from 240 NSCLC patients with EGFR L833 and H835 mutations were analyzed, including 57 with documented EGFR-TKI treatment records. Additionally, an external cohort of 346 NSCLC patients with EGFR L858R mutations and wild-type EGFR L833 and H835 was evaluated for comparative analyses of molecular landscapes. Kaplan-Meier survival curves were generated, and the log-rank test was employed to compare survival times between subtypes.Results:In the study cohort, 98.3% (235/239) of patients with EGFR L833 mutations and 100% (82/82) with EGFR H835 mutations had concurrent EGFR mutations. Interestingly, 97.5% (78/80) of patients with EGFR H835L mutations had concurrent L833V mutations, while the most frequent co-mutations of EGFR L833V being L858R (44.1%, 93/211) and H835L (37.0%, 78/211). Compared to EGFR L858R patients in the external cohort, those with EGFR L833V+H835L and L833V+L858R mutations had lower frequencies of LRP1B, RB1, TP53 mutations, as well as CD4K amplifications and mutations in the RTK-RAS and cell cycle signaling pathways. Tumor mutational burden (TMB), chromosomal stability, whole-genome duplication rates, and age-related and APOBEC-associated mutational signatures were also lower in patients with EGFR L833V+H835L and L833V+L858R mutations compared to those with EGFR L858R, with significant differences in TMB (P = 0.110 and P = 0.001), chromosomal instability (P = 0.036 and P = 0.042), whole-genome duplication rates (P = 0.008 and P = 0.028), age-related signatures (P = 0.006 and P = 0.027), and APOBEC-associated signatures (both P < 0.001). Notably, EGFR-TKI efficacy data revealed that patients with EGFR L833 and H835 mutations can benefit from EGFR-TKI treatment, with a median progression-free survival (PFS) of 16.4 months. PFS was comparable across mutation subtypes (L833V+H835L vs. L833V+L858R vs. others, P = 0.096) and across different generations of EGFR-TKIs received (P = 0.533).Conclusion:This study demonstrates that patients with EGFR L833 and H835 mutations can benefit from EGFR-TKIs, with comparable median PFS to those with classical EGFR L858R mutations in previous literatures. Additionally, patients with L833 and H835 mutations displayed distinct molecular features compared to L858R, characterized by lower TP53 mutation frequencies, lower TMB values, and lower chromosomal instability.Citation Format:Nong Yang, Long Huang, Dou Ren, Fanxu Zeng, Chengchuan Jiang, Weiwei Zhang, Weifeng He, Wei Yin, Peng Huang, Hanlin Chen, Xiaoying Wu, Jiaohui Pang, Haimeng Tang, Xue Wu, Qiuxiang Ou. Mutational landscape and tyrosine kinase inhibitor sensitivity in EGFR L833 and H835 mutated non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 5357.

01 Apr 2025·Journal of Genetics and Genomics

Multiple nucleotide variants in genetic diagnosis: implications from 11,467 cases of hearing loss

Article

Author: Lu, Yu ; Zhang, Qian ; Chen, Meilin ; Zhong, Mingjun ; Cheng, Jing ; Chen, Lei ; Bu, Fengxiao ; Zeng, Jiayi ; Yuan, Huijun ; Ai, Fandi

Multiple nucleotide variants (MNVs) are frequently misannotated as separate single-nucleotide variants (SNVs) by widely utilized variant-calling pipelines, presenting substantial challenges in genetic testing and research. The role of MNVs in genetic diagnosis remains inadequately characterized, particularly within large disease cohorts. In this study, we comprehensively investigate codon-level MNVs (cMNVs) across 157 hearing loss (HL)-related genes in 11,467 HL cases and 7,258 controls from the Chinese Deafness Gene Consortium (CDGC) cohort. A total of 116 cMNVs are identified, occurring in 29.07% of HL cases. 56.03% of cMNVs exhibit functional consequences distinct from constituent SNVs. Moreover, amino acid substitutions exclusive to cMNVs cause more substantial physicochemical disruptions than those associated with SNVs. Notably, 51 cMNVs show pathogenicity classifications that diverge from at least one constituent SNV, impacting genetic interpretation in 145 cases. Pathogenicity interpretation of cMNV facilitates definitive genetic diagnoses in eight HL cases that would otherwise have been subject to misdiagnoses or missed diagnoses. These findings provide critical insights into the genomic characteristics, functional impacts, and diagnostic implications of cMNVs, underscoring their clinical significance in genetic diagnosis and emphasizing the necessity for comprehensive and accurate detection and interpretation of cMNVs in genetic testing and research.

100 Deals associated with The Second People's Hospital of Hunan Province

100 Translational Medicine associated with The Second People's Hospital of Hunan Province

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 09 Jul 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Oligomeric proanthocyanidin ( Malondialdehyde )	Liver Cancer More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis